Fig. 1From: High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer InstitutePFS and OS Analyses By Response to HD IL-2 Therapy. a and b Kaplan-Meier plots of progression free survival (a) and overall survival (b) after HD IL-2 therapy are compared by response to therapy (CR/PR vs. SD/PD). All p-values significantBack to article page